A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo–Pyrazole Treatment in SKMEL-28 Melanoma Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126760 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Erika Iervasi und 10 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go. R. Benzi, 10, 16132 Genova, Italy. Hauptthemen laut MEDLINE: Melanoma, Pyrazoles, Proteomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (Ricerca Corrente), “Più unici che rari” OdV.
Abstract (Originalsprache)
Cutaneous melanoma is the most dangerous and deadly form of human skin malignancy. Despite its rarity, it accounts for a staggering 80% of deaths attributed to cutaneous cancers overall. Moreover, its final stages often exhibit resistance to drug treatments, resulting in unfavorable outcomes. Hence, ensuring access to novel and improved chemotherapeutic agents is imperative for patients grappling with this severe ailment. Pyrazole and its fused systems derived thereof are heteroaromatic moieties widely employed in medicinal chemistry to develop effective drugs for various therapeutic areas, including inflammation, pain, oxidation, pathogens, depression, and fever. In a previous study, we described the biochemical properties of a newly synthesized group of imidazo–pyrazole compounds. In this paper, to improve our knowledge of the pharmacological properties of these molecules, we conduct a differential proteomic analysis on a human melanoma cell line treated with one of these imidazo–pyrazole derivatives. Our results detail the changes to the SKMEL-28 cell line proteome induced by 24, 48, and 72 h of 3e imidazo–pyrazole treatment. Notably, we highlight the down-regulation of the Ras-responsive element binding protein 1 (RREB1), a member of the zinc finger transcription factors family involved in the tumorigenesis of melanoma. RREB1 is a downstream element of the MAPK pathway, and its activation is mediated by ERK1/2 through phosphorylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go. R. Benzi, 10, 16132 Genova, Italy.
- Department of Pharmacy, Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy.
- IRCCS Ospedale Policlinico San Martino, Nuclear Medicine Unit, L.go. R. Benzi, 10, 16132 Genova, Italy.
ORCID-Profile: Erika Iervasi, Gabriela Coronel Vargas, Andrea Spallarossa, Chiara Brullo, Camillo Rosano, Sonia Carta, Paola Barboro, Aldo Profumo, Marco Ponassi
Förderung
- Italian Ministry of Health (Ricerca Corrente)
- “Più unici che rari” OdV
Zitieren
APA
Iervasi, E., Coronel Vargas, G., Bachetti, T., Tkachenko, K., Spallarossa, A., Brullo, C., Rosano, C., Carta, S., Barboro, P., Profumo, A., & Ponassi, M. (2024). A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo–Pyrazole Treatment in SKMEL-28 Melanoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126760
Vancouver
Iervasi E, Coronel Vargas G, Bachetti T, Tkachenko K, Spallarossa A, Brullo C, et al. A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo–Pyrazole Treatment in SKMEL-28 Melanoma Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126760
BibTeX
@article{Iervasi2024,
author = {Iervasi, Erika and Coronel Vargas, Gabriela and Bachetti, Tiziana and Tkachenko, Kateryna and Spallarossa, Andrea and Brullo, Chiara and Rosano, Camillo and Carta, Sonia and Barboro, Paola and Profumo, Aldo and Ponassi, Marco},
title = {A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo–Pyrazole Treatment in SKMEL-28 Melanoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126760}
}
EUVIMED